WO1999048479A1 - Mikrokapseln mit verzögertem release - Google Patents
Mikrokapseln mit verzögertem release Download PDFInfo
- Publication number
- WO1999048479A1 WO1999048479A1 PCT/EP1999/001625 EP9901625W WO9948479A1 WO 1999048479 A1 WO1999048479 A1 WO 1999048479A1 EP 9901625 W EP9901625 W EP 9901625W WO 9948479 A1 WO9948479 A1 WO 9948479A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acid
- solution
- microcapsules
- chitosan
- hcl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/11—Encapsulated compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/736—Chitin; Chitosan; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q13/00—Formulations or additives for perfume preparations
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/02—Making microcapsules or microballoons
- B01J13/06—Making microcapsules or microballoons by phase separation
- B01J13/10—Complex coacervation, i.e. interaction of oppositely charged particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns
Definitions
- the present invention relates to microcapsules with a greatly delayed release of the active ingredients.
- microcapsules is understood to mean capsules with a size of 50 nm to 3 mm, which have an outer shell made of polymers and an inner, usually liquid phase. Microcapsules are usually produced by encapsulating finely dispersed liquid phases by coating with film-forming polymers. Such microcapsules are used above all in the field of depot preparations, according to which the active substance located in the inner phase of the microcapsules is protected by the shell of the microcapsule and is not released immediately but only with a delayed release (active substance release).
- US-A-4,352,883 describes a two-stage process for producing microcapsules in which living cells, such as, for example, Langerhans islet cells, are encapsulated.
- living cells such as, for example, Langerhans islet cells
- the living cells are suspended in sodium alginate and this suspension is sprayed into a precipitation bath which contains polyvalent cations (for example Ca 2+ ).
- polyvalent cations for example Ca 2+
- the capsules produced in this way are mixed with a cationic polymer, which brings about further physical crosslinking.
- Polyethyleneimine and polylysine are mentioned as polycations in this publication.
- capsules are for proteins with a molecular weight less than 100,000 g / mol completely permeable. There is therefore no delayed release of these substances.
- US-A-5 389 379 discloses a method for producing microcapsules in which the liquid droplets produced by means of an ultrasound nozzle are first introduced into a liquid in which the liquid droplets are not soluble (for example in ethanol). This liquid is then replaced by water in order to crosslink the microcapsules.
- Chitossan is the general term for a polymer produced by deacetylating chitin, an unbranched ⁇ (1-4) -linked polysaccharide of 2-acetamido-2-deoxy-D-glucose (N-acetyl-D-glucosamine) , is available.
- the ratio of deacetylated to acetylated segments is greater than 1 and the number average molecular weight is between 50,000 and several million g / mol.
- This chitosan is insoluble in water and can be obtained, for example, from Fluka. This is how CA. McKnight et al. in Journal of Bioactive and Compatible Poly- 3 mers, Vol. 3, 1988, pp. 334 to 355 a three-stage process for the production of microcapsules based on alginate and chitosan. According to this method, the alginate solution containing the active ingredient is first introduced into a calcium chloride solution, where the outer capsule surface is first hardened.
- the hardened capsules are then coated with a chitosan solution, which leads to a cross-linking of the outer shell. Finally, the microcapsules obtained in this way are washed with alginate.
- the chitosan used in this publication has a number average molecular weight of 160,000 to 330,000. Permeability studies of these chitosan / alginate membranes have shown that the molecular weight of the chitosan used has no significant influence on the permeation behavior of various proteins. After only two hours, 20% of the active ingredient BSA has diffused into the microcapsules containing chitosan. The release of these microcapsules is already very high after a short time.
- a disadvantage of the known processes for producing chitosan-containing microcapsules is that they are produced in two or more different working steps. Above all, the transportation of the microcapsules from one reaction container to the other requires complex devices, especially when small microcapsules are to be produced. 4
- the object of the present invention is to provide microcapsules which have a delayed release of the active compounds compared to the known prior art.
- these microcapsules are said to be easy to manufacture.
- the weight ratio of HCl-containing solution to commercial chitosan is between 1 and 50 and the product of normality of the HCl solution and the hydrolysis time in hours is between 0.1 and 7; and b) after the addition of solution 1 has ended for a period of 15 to 360 minutes, in particular for a period of 60 to 180 minutes, the microcapsules thus obtained remain in solution 2.
- microcapsules produced according to the invention show a significantly reduced permeability compared to the chitosan-containing microcapsules of the prior art. After 10 days of measurement, the release of the microcapsules produced according to the invention is still below 50% (active ingredient: bovine serum albumin).
- active ingredient bovine serum albumin
- the process according to the invention has the advantage that the microcapsules are produced in a single process step. The elaborate devices which were previously necessary in the multi-stage processes of the prior art for transporting the microcapsules are thus eliminated. 5
- the aqueous solution 1 can be converted into liquid droplets by methods known per se. In particular, commercially available atomizers can be used for this.
- the water-soluble polyanion is an alginate, in particular an alginate with a high guluronic acid content.
- the water-soluble polyanion can also be selected from the group of carrageenan, sulfated polysaccharides, gelatin and agar.
- solution 1 additionally contains at least one polyacid or its alkali salt, selected from the group of polyamino acids, polyphosphates and polysulfates of polysaccharides.
- Preferred examples of a polyphosphate are sodium polyphosphate and a polyphosphate of a polysaccharide.
- the polysaccharide can be selected from the group of starch hydrolyzates,
- Polyaspartic acid or polyglutamic acid is preferably used as the polyamino acid.
- solution 2 additionally contains a polycation selected from the group consisting of polyiysin, polyvinylamine, poly- ⁇ , ⁇ - (2-2dimethylaminoethyl) -D, L-aspartamide, aminated polysaccharides, such as e.g. aminated dextrans, cyclodextrins, cellulose ethers, starches, pectins, and their hydrophobically substituted derivatives.
- a polycation selected from the group consisting of polyiysin, polyvinylamine, poly- ⁇ , ⁇ - (2-2dimethylaminoethyl) -D, L-aspartamide, aminated polysaccharides, such as e.g. aminated dextrans, cyclodextrins, cellulose ethers, starches, pectins, and their hydrophobically substituted derivatives.
- the release can also be reduced by reacting the microcapsules with a crosslinker in an additional process step, selected from the group of glyoxal, glutardialdehyde, succinic acid dialdehyde, or dicarboxylic acids, such as oxalic acid, succinic acid, fumaric acid, maleic acid, in an additional process step.
- a crosslinker selected from the group of glyoxal, glutardialdehyde, succinic acid dialdehyde, or dicarboxylic acids, such as oxalic acid, succinic acid, fumaric acid, maleic acid, in an additional process step.
- diacid chlorides such as succinic acid chloro- 6 rid, fumaric acid chloride, glutaric acid chloride, adipic acid chloride, or tricarboxylic acids, such as citric acid, 1,2,3-propane tricarboxylic acid, hemimellitic acid, trimellitic acid, trimesic acid.
- the size of the microcapsules produced according to the invention is between 1 and 3,000 ⁇ m, in particular between 10 and 1,000 ⁇ m.
- microcapsules according to the invention are preferably used as carriers for active substances, in particular for pharmaceuticals, food additives, flavors, fragrances, colorants, herbicides, fungicides, bactericides, pesticides and insecticides.
- Solution 1 is dripped into solution 2 by means of a nozzle consisting of a cannula with an inner diameter of 0.2 mm and an outer diameter of 0.4 mm.
- the nozzle is embedded concentrically in a hollow cylinder, so that a tangential air flow can be generated via the resulting annular gap, which entrains the drops emerging from the cannula. The drops thus created fall into solution 2.
- microcapsules formed After 1 ml of solution 1 has been introduced into 15 ml of solution 2, the microcapsules formed are allowed to sediment and the solution is decanted off. The microcapsules obtained are then suspended three times with 0.9% NaCl solution. The most common size of the microcapsules produced in this way was determined by diffraction of women and was 90 ⁇ m.
- the model protein BSA-FITC from Sigma (catalog number: A-9771) is used.
- Other materials are: Nathum alginate from Sigma (A-7128), Chitosan from Fluka (22743), CaCI 2 from Riedel de Haen (12018), NaCI from Merck (6404).
- the release measurements are carried out in PBS buffer (Sigma, P4417), with an additional 0.005% timerosol (from Fluka, catalog number: 71230).
- the PEC capsules are transferred to 10 ml PBS buffer solution, in 15 ml crimp-top vials, and the microcapsules are incubated at 37 ° C.
- the BSA-FITC concentration was measured using a UV / VIS spectrophotomer from Beckmann (DU 70). First, the proportion of trapped BSA-FITC is determined by determining the BSA-FITC concentration in the combined supernatants. The concentration is determined by measuring the absorption at 494 nm using a calibration curve. A falsification of the measurement due to the intrinsic coloration of the chitosan is avoided by the absorption 8 tion of the chitosan is withdrawn. The amount of BSA-FITC used can be used to calculate how much of the BSA-FITC was included.
- the release measurement is carried out by taking 3 ml from the incubation solution and determining the BSA-FITC concentration on this supernatant. After the measurement is completed, the sample solution is combined with the release sample. The release of the microcapsules obtained in this way is only 20% of the encapsulated active ingredient after 11 days.
- Example 2 The procedure is analogous to Example 1. After the microparticle production, the particles are crosslinked with glyoxal. For this purpose, the microparticles are placed in 10 ml of a 2% by weight glyoxal solution for 30 minutes and left to stand. Then they are washed with 0.9% NaCl solution. The release of the microcapsules obtained in this way is less than 10% of the encapsulated active ingredient after 45 days.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Birds (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Manufacturing Of Micro-Capsules (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU28365/99A AU736941B2 (en) | 1998-03-25 | 1999-03-12 | Microcapsules having delayed release |
EP99908958A EP1063970A1 (de) | 1998-03-25 | 1999-03-12 | Mikrokapseln mit verzögertem release |
JP2000537529A JP2002507472A (ja) | 1998-03-25 | 1999-03-12 | 放出の遅いマイクロカプセル |
CA002325554A CA2325554A1 (en) | 1998-03-25 | 1999-03-12 | Microcapsules having delayed release |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19813010.4 | 1998-03-25 | ||
DE1998113010 DE19813010A1 (de) | 1998-03-25 | 1998-03-25 | Mikrokapseln mit verzögertem Release |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999048479A1 true WO1999048479A1 (de) | 1999-09-30 |
Family
ID=7862189
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1999/001625 WO1999048479A1 (de) | 1998-03-25 | 1999-03-12 | Mikrokapseln mit verzögertem release |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1063970A1 (de) |
JP (1) | JP2002507472A (de) |
AU (1) | AU736941B2 (de) |
CA (1) | CA2325554A1 (de) |
DE (1) | DE19813010A1 (de) |
WO (1) | WO1999048479A1 (de) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001028524A1 (en) * | 1999-10-18 | 2001-04-26 | Epic Therapeutics, Inc. | Sustained release microspheres |
WO2001047626A1 (de) * | 1999-12-23 | 2001-07-05 | Henkel Kommanditgesellschaft Auf Aktien | Gefärbte chitosan-kapseln |
WO2001047625A1 (de) * | 1999-12-23 | 2001-07-05 | Henkel Kommanditgesellschaft Auf Aktien | Pigmentierte chitosan-kapseln |
WO2001098578A1 (de) * | 2000-06-20 | 2001-12-27 | Primacare S. L. | Textilhilfsmittel |
WO2003094887A1 (en) * | 2002-05-09 | 2003-11-20 | Peptron Co., Ltd | Sustained release formulation of protein and preparation method thereof |
WO2008157514A2 (en) * | 2007-06-14 | 2008-12-24 | Genesegues, Inc. | Metal ion-treated biocompatible polymers useful for nanoparticles |
US8067020B2 (en) | 2001-06-21 | 2011-11-29 | Genetech, Inc. | Sustained release formulation |
WO2016108234A1 (en) * | 2014-12-30 | 2016-07-07 | Yissum Research Develoment Company Of The Hebrew University Of Jerusalem Ltd. | Liquid-core capsules comprising non-crosslinked alginate |
US10385296B2 (en) | 2017-03-16 | 2019-08-20 | The Procter & Gamble Company | Methods for making encapsulate-containing product compositions |
US10385297B2 (en) | 2017-03-16 | 2019-08-20 | The Procter & Gamble Company | Methods for making encapsulate-containing product compositions |
US10611988B2 (en) | 2017-03-16 | 2020-04-07 | The Procter & Gamble Company | Methods for making encapsulate-containing product compositions |
US10987308B2 (en) | 2014-09-03 | 2021-04-27 | Genesegues, Inc. | Therapeutic nanoparticles and related compositions, methods and systems |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1243319A1 (de) * | 2001-03-22 | 2002-09-25 | Primacare S.L., c/o Cognis Iberica S.L. | Mikrokapseln (XI) |
DE50105470D1 (de) * | 2001-03-22 | 2005-04-07 | Primacare S L | Mikrokapseln (XII) |
US6723359B2 (en) * | 2001-10-18 | 2004-04-20 | Firmenich Sa | Spray-dried compositions and method for their preparation |
DE10164137B4 (de) * | 2001-12-30 | 2016-04-28 | Henkel Ag & Co. Kgaa | Wasch-, Reinigungs- und/oder Pflegemittel-Formulierung enthaltender Formkörper mit erhöhter Lagerstabilität sowie Verfahren zu seiner Herstellung |
EP1837074A1 (de) * | 2006-03-20 | 2007-09-26 | Cognis IP Management GmbH | Verfahren zur Herstellung von Mikrokapseln mit kontrollierter Härte |
WO2008037578A1 (en) * | 2006-09-29 | 2008-04-03 | Unilever Plc | Compounds, which are starch containing particles coated, embedded or encapsulated by at least one biopolymer in a multilayer arrangement |
WO2008037576A1 (en) * | 2006-09-29 | 2008-04-03 | Unilever Plc | Process for production of compounds, which are starch containing particles coated, embedded or encapsulated by at least one biopolymer |
CN102960599A (zh) * | 2012-11-19 | 2013-03-13 | 陕西科技大学 | 一种含益生元的双歧杆菌微胶囊的制备方法 |
CN107712543B (zh) * | 2017-09-20 | 2021-04-16 | 徐宝军 | 一种抗絮凝姜黄素微胶囊、制备方法及其应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5974984A (ja) * | 1982-10-21 | 1984-04-27 | Sumitomo Chem Co Ltd | 固定化酵素もしくは固定化微生物の製造方法 |
JPH05238957A (ja) * | 1992-02-28 | 1993-09-17 | Kibun Food Chemifa Co Ltd | 徐放性組成物 |
-
1998
- 1998-03-25 DE DE1998113010 patent/DE19813010A1/de not_active Withdrawn
-
1999
- 1999-03-12 EP EP99908958A patent/EP1063970A1/de not_active Withdrawn
- 1999-03-12 AU AU28365/99A patent/AU736941B2/en not_active Ceased
- 1999-03-12 WO PCT/EP1999/001625 patent/WO1999048479A1/de active IP Right Grant
- 1999-03-12 JP JP2000537529A patent/JP2002507472A/ja active Pending
- 1999-03-12 CA CA002325554A patent/CA2325554A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5974984A (ja) * | 1982-10-21 | 1984-04-27 | Sumitomo Chem Co Ltd | 固定化酵素もしくは固定化微生物の製造方法 |
JPH05238957A (ja) * | 1992-02-28 | 1993-09-17 | Kibun Food Chemifa Co Ltd | 徐放性組成物 |
Non-Patent Citations (7)
Title |
---|
DATABASE WPI Section Ch Week 8423, Derwent World Patents Index; Class A10, AN 84-143230, XP002112139 * |
DATABASE WPI Section Ch Week 9342, Derwent World Patents Index; Class B04, AN 93-331371, XP002112138 * |
MC KNIGHT C.A. ET AL: "Synthesis of Chitosan-alginate microcapsules membranes", J. OF BIOACTIVE AND COMPATIBLE POLYMERS, vol. 3, 1988, pages 334 - 355, XP002112137 * |
MURATA Y ET AL: "ADDITIVE EFFECT OF CHONDROITIN SULFATE AND CHITOSAN ON DRUG RELEASEFROM CALCIUM-INDUCED ALGINATE GEL BEADS", JOURNAL OF CONTROLLED RELEASE, vol. 38, no. 2/03, 1 February 1996 (1996-02-01), pages 101 - 108, XP000558704, ISSN: 0168-3659 * |
OKHAMAFE A O ET AL: "MODULATION OF PROTEIN RELEASE FROM CHITOSAN-ALGINATE MICROCAPSULES USING THE PH-SENSITIVE POLYMER HYDROXYPROPYL METHYLCELLULOSE ACETATE SUCCINATE", JOURNAL OF MICROENCAPSULATION, vol. 13, no. 5, 1 September 1996 (1996-09-01), pages 497 - 508, XP000599283, ISSN: 0265-2048 * |
PATENT ABSTRACTS OF JAPAN vol. 008, no. 178 (C - 238) 16 August 1984 (1984-08-16) * |
POLK A. ET AL: "Controlled release of albumin from chitosan-alginate microcapsules", J. OF PHARM. SCIENCES, vol. 83, no. 2, 1994, pages 178 - 185, XP002112136 * |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6458387B1 (en) | 1999-10-18 | 2002-10-01 | Epic Therapeutics, Inc. | Sustained release microspheres |
EP1837018A1 (de) * | 1999-10-18 | 2007-09-26 | Baxter International Inc. | Mikrosphären mit verzögerter Wirkstoffabgabe |
WO2001028524A1 (en) * | 1999-10-18 | 2001-04-26 | Epic Therapeutics, Inc. | Sustained release microspheres |
WO2001047626A1 (de) * | 1999-12-23 | 2001-07-05 | Henkel Kommanditgesellschaft Auf Aktien | Gefärbte chitosan-kapseln |
WO2001047625A1 (de) * | 1999-12-23 | 2001-07-05 | Henkel Kommanditgesellschaft Auf Aktien | Pigmentierte chitosan-kapseln |
WO2001098578A1 (de) * | 2000-06-20 | 2001-12-27 | Primacare S. L. | Textilhilfsmittel |
EP1167618A1 (de) * | 2000-06-20 | 2002-01-02 | Primacare S.A. | Textilhilfsmittel |
US8067020B2 (en) | 2001-06-21 | 2011-11-29 | Genetech, Inc. | Sustained release formulation |
WO2003094887A1 (en) * | 2002-05-09 | 2003-11-20 | Peptron Co., Ltd | Sustained release formulation of protein and preparation method thereof |
WO2008157514A2 (en) * | 2007-06-14 | 2008-12-24 | Genesegues, Inc. | Metal ion-treated biocompatible polymers useful for nanoparticles |
WO2008157514A3 (en) * | 2007-06-14 | 2009-03-19 | Genesegues Inc | Metal ion-treated biocompatible polymers useful for nanoparticles |
US10987308B2 (en) | 2014-09-03 | 2021-04-27 | Genesegues, Inc. | Therapeutic nanoparticles and related compositions, methods and systems |
WO2016108234A1 (en) * | 2014-12-30 | 2016-07-07 | Yissum Research Develoment Company Of The Hebrew University Of Jerusalem Ltd. | Liquid-core capsules comprising non-crosslinked alginate |
US10413515B2 (en) | 2014-12-30 | 2019-09-17 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Liquid-core capsules comprising non-crosslinked alginate |
US10385296B2 (en) | 2017-03-16 | 2019-08-20 | The Procter & Gamble Company | Methods for making encapsulate-containing product compositions |
US10385297B2 (en) | 2017-03-16 | 2019-08-20 | The Procter & Gamble Company | Methods for making encapsulate-containing product compositions |
US10611988B2 (en) | 2017-03-16 | 2020-04-07 | The Procter & Gamble Company | Methods for making encapsulate-containing product compositions |
Also Published As
Publication number | Publication date |
---|---|
EP1063970A1 (de) | 2001-01-03 |
AU2836599A (en) | 1999-10-18 |
JP2002507472A (ja) | 2002-03-12 |
CA2325554A1 (en) | 1999-09-30 |
AU736941B2 (en) | 2001-08-09 |
DE19813010A1 (de) | 1999-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1999048479A1 (de) | Mikrokapseln mit verzögertem release | |
Remuñán-López et al. | Effect of formulation and process variables on the formation of chitosan-gelatin coacervates | |
EP1012204B1 (de) | Sphärische lineare polysaccharide enthaltende mikropartikel | |
EP1098696B2 (de) | Polyelektrolythüllen auf biologischen templaten | |
US5562924A (en) | Polysaccharide wall microcapsules containing primary alcohol functions and compositions containing same | |
EP0454044B1 (de) | Pharmakologische Zubereitung, enthaltend Polyelektrolytkomplexe in mikropartikulärer Form und mindestens einen Wirkstoff | |
DE19839214C1 (de) | Verfahren zur Herstellung von sphärischen Mikropartikeln mit glatter Oberfläche, die ganz oder teilweise aus mindestens einem wasserunlöslichen linearen Polysaccharid bestehen, sowie mit diesem Verfahren erhältliche Mikropartikel und deren Verwendung | |
WO2002038132A2 (de) | Weichkapseln umfassend ein stärkegemisch verringerten verzweigungsgrades | |
DE69729312T2 (de) | Mikropartikel mit gesteuerter Freisetzung | |
DE69826119T2 (de) | Heteropolysaccharid-konjugate, halbinterpenetrierende polysaccharidgele und verfahren zu deren herstellung | |
JPH04281836A (ja) | ポリサッカライド製品およびその用途 | |
US20090117195A1 (en) | Hydrophilic Particles Based on Cationic Chitosan Derivatives | |
EP1066031A2 (de) | Verfahren zur herstellung von mikrokapseln | |
DE19839212C2 (de) | Verfahren zur Herstellung von sphärischen Nanopartikeln, die ganz oder teilweise aus mindestens einem wasserunlöslichen linearen Polysaccharid bestehen | |
DE3590071T1 (de) | Kapseln und Verfahren zu ihrer Herstellung | |
Hooda et al. | Chitosan nanoparticles: A marine polysaccharide for biomedical research | |
DE102011055861B4 (de) | Verfahren zur Herstellung monodisperser Pektin-Mikrogele unter Verwendung eines mikrofluidischen Systems | |
CN102010527B (zh) | 壳聚糖纳米粒及其制备方法 | |
CN110938156A (zh) | 一种两亲性壳聚糖及其制备方法和应用其的两亲性壳聚糖基纳米微胶囊 | |
DE19860373B4 (de) | Mundpflegemittel und Verwendung von sphärischen Mikropartikeln | |
DE2441890A1 (de) | Verfahren zur herstellung von gelatinemikrokapseln mit fluessigem bzw. festem inhalt | |
DE19847593A1 (de) | Zusammensetzung für die parenterale Applikation von Wirkstoffen | |
EP1139978A1 (de) | Sonnenschutzmittel mit mikropartikeln auf basis von wasserunlöslichem linearem polyglucan | |
DE4416001C2 (de) | Komposite zur steuerbaren Wirkstoff-Freisetzung | |
DD275696A1 (de) | Verfahren zur herstellung von sphaerischen traegermaterialien |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1999908958 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09646630 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2325554 Country of ref document: CA Ref country code: CA Ref document number: 2325554 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 28365/99 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 1999908958 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999908958 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 28365/99 Country of ref document: AU |